NASDAQ:JBIO

Jade Biosciences Q3 2025 Earnings Results & Report

Jade Biosciences logo
$15.40 +0.06 (+0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$15.44 +0.04 (+0.26%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jade Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.48 versus the -$0.57 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call
7:00 AM ET

Jade Biosciences EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Q3 2025 Earnings FAQ

Jade Biosciences (NASDAQ:JBIO) reported earnings of -$0.48 per share for Q3 2025, beating the consensus estimate of -$0.57. The report was announced on Friday, November 14, 2025.

Jade Biosciences Earnings Headlines

Jade Biosciences (JBIO) Stock Price Target 2026
Jade Biosciences (NASDAQ:JBIO) Upgraded at Wall Street Zen
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease.

The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys.

Jade’s pipeline is focused on potential therapies for autoimmune conditions. The company’s work is at the drug-development stage, and its programs are intended to address diseases with significant unmet treatment needs.

View Jade Biosciences Profile